image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.5884
-6.19 %
$ 56.4 M
Market Cap
-2.56
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ASRT stock under the worst case scenario is HIDDEN Compared to the current market price of 0.588 USD, Assertio Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ASRT stock under the base case scenario is HIDDEN Compared to the current market price of 0.588 USD, Assertio Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ASRT stock under the best case scenario is HIDDEN Compared to the current market price of 0.588 USD, Assertio Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ASRT

image
$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.515 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
125 M REVENUE
-17.83%
-24.5 M OPERATING INCOME
89.95%
-21.6 M NET INCOME
93.50%
26.4 M OPERATING CASH FLOW
-46.76%
-48.9 M INVESTING CASH FLOW
-1579.30%
-350 K FINANCING CASH FLOW
99.21%
32.2 M REVENUE
10.20%
-13.5 M OPERATING INCOME
-342.09%
-10.5 M NET INCOME
-258.64%
11.5 M OPERATING CASH FLOW
33094.29%
1.12 M INVESTING CASH FLOW
116.66%
-59 K FINANCING CASH FLOW
-490.00%
Balance Sheet Assertio Holdings, Inc.
image
Current Assets 203 M
Cash & Short-Term Investments 100 M
Receivables 54.1 M
Other Current Assets 48.4 M
Non-Current Assets 82.2 M
Long-Term Investments 0
PP&E 586 K
Other Non-Current Assets 81.6 M
35.14 %19.01 %16.99 %28.66 %Total Assets$284.7m
Current Liabilities 115 M
Accounts Payable 14.7 M
Short-Term Debt 0
Other Current Liabilities 100 M
Non-Current Liabilities 49 M
Long-Term Debt 38.8 M
Other Non-Current Liabilities 10.2 M
9.00 %61.08 %23.72 %6.20 %Total Liabilities$163.7m
EFFICIENCY
Earnings Waterfall Assertio Holdings, Inc.
image
Revenue 125 M
Cost Of Revenue 39.2 M
Gross Profit 85.7 M
Operating Expenses 110 M
Operating Income -24.5 M
Other Expenses -2.9 M
Net Income -21.6 M
140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)125m(39m)86m(110m)(24m)3m(22m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.61% GROSS MARGIN
68.61%
-19.59% OPERATING MARGIN
-19.59%
-17.19% NET MARGIN
-17.19%
-17.74% ROE
-17.74%
-7.54% ROA
-7.54%
-14.36% ROIC
-14.36%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Assertio Holdings, Inc.
image
120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -21.6 M
Depreciation & Amortization 25.8 M
Capital Expenditures 0
Stock-Based Compensation 5.01 M
Change in Working Capital 5.2 M
Others 34.4 M
Free Cash Flow 26.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Assertio Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for ASRT of $2.5 , with forecasts ranging from a low of $1.75 to a high of $3 .
ASRT Lowest Price Target Wall Street Target
1.75 USD 197.42%
ASRT Average Price Target Wall Street Target
2.5 USD 324.88%
ASRT Highest Price Target Wall Street Target
3 USD 409.86%
Price
Max Price Target
Min Price Target
Average Price Target
333322221111May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Assertio Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
70 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
35.4 K USD 2
9-12 MONTHS
7. News
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025 LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring Investment Conference taking place virtually March 25-26, 2025. globenewswire.com - 1 month ago
Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Matthew Kreps - IR Brendan O'Grady - CEO Ajay Patel - CFO Conference Call Participants James Sidoti - Sidoti & Company Thomas Flaten - Lake Street Capital Markets, LLC Naz Rahman - Maxim Group Scott Henry - AGP Operator Thank you for standing by. My name is Eric, and I'll be your conference operator today. seekingalpha.com - 1 month ago
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 1 month ago
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. globenewswire.com - 1 month ago
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel CHICAGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed in Lake County Circuit Court, Nineteenth Judicial Circuit, State of Illinois, on behalf of all persons and entities who acquired Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio” or the “Company”) common stock issued in exchange for Spectrum Pharmaceuticals, Inc. (“Spectrum”) common stock in connection with Assertio's July 31, 2023 merger with Spectrum (the “Merger”), charging the Company and certain of its current and former senior executives and directors with violations of the federal securities laws (collectively, “Defendants”). globenewswire.com - 2 months ago
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective December 23, 2024, the Compensation Committee of the Company's Board of Directors granted Mary Pietryga, the Company's newly-hired Senior Vice President, Chief Commercial Officer, 62,500 restricted stock units (“RSUs”) and 275,000 stock options (“options”). globenewswire.com - 3 months ago
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. globenewswire.com - 4 months ago
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon ® (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer (ESBC). globenewswire.com - 4 months ago
New Strong Buy Stocks for December 10th CTV, GRAB, ASRT, POWL and LUV have been added to the Zacks Rank #1 (Strong Buy) List on December 10, 2024. zacks.com - 4 months ago
New Strong Buy Stocks for November 29th MKTAY, ASRT, CHH, DRS and BRKL have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2024. zacks.com - 4 months ago
Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that recently inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today called upon the Senate Committee on Health, Education, Labor & Pensions (the “Committee”) to investigate the evident product-related fraud at. businesswire.com - 5 months ago
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT ) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - CEO Ajay Patel - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners Raghuram Selvaraju - H.C. Wainwright Operator Thank you for standing by. seekingalpha.com - 5 months ago
8. Profile Summary

Assertio Holdings, Inc. ASRT

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 56.4 M
Dividend Yield 0.00%
Description Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Contact 100 South Saunders Road, Lake Forest, IL, 60045 https://www.assertiotx.com
IPO Date Dec. 3, 1997
Employees 58
Officers Mr. Ajay Patel Executive Vice President & Chief Financial Officer Mr. Sam Schlessinger Executive Vice President & General Counsel Mr. Paul Schwichtenberg Executive Vice President & Chief Transformation Officer Mr. Brendan P. O'Grady Chief Executive Officer & Director Ms. Mary Pietryga Chief Commercial Officer Ms. Molly Dir Senior Vice President of HR & Administration Mr. Bill Iskos Senior Vice President of Operations Dr. Howard J. Franklin M.B.A., M.D. Senior Vice President of Medical